Cart
sales@molnova.com
Thalidomide-O-C4-NH2 hydrochloride
CAS No. 2376990-29-1
Thalidomide-O-C4-NH2 hydrochloride( Thalidomide-linker 9 | Thalidomide-O-C4-NH2 hydrochloride )
Catalog No. M28663 CAS No. 2376990-29-1
Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 42 | In Stock |
|
| 10MG | 59 | In Stock |
|
| 25MG | 88 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameThalidomide-O-C4-NH2 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionThalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
DescriptionThalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
In Vitro——
-
In Vivo——
-
SynonymsThalidomide-linker 9 | Thalidomide-O-C4-NH2 hydrochloride
-
PathwayOthers
-
TargetOther Targets
-
RecptorCytochrome P450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2376990-29-1
-
Formula Weight381.81
-
Molecular FormulaC17H20ClN3O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3OCCCCN)=O.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hoyt SB, et al. Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.ACS Med Chem Lett. 2015 Apr 7;6(5):573-8.
molnova catalog
related products
-
(2R3S)-3-Phenylisose...
(2R,3S)-3-Phenylisoserine hydrochloride is a serine derivative.
-
SSD114 hydrochloride
SSD114 hydrochloride is a GABAB receptor positive allosteric modulator.
-
Glenzocimab
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
